LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix Inc., a biotechnology company commercializing a broad new class of treatments for respiratory disease, announced today the appointment of John P. Hanrahan, M.D., M.P.H., as Senior Vice President and Chief Medical Officer. Dr. Hanrahan will lead the Company’s clinical development programs beginning with Phase II trials assessing the efficacy of Pulmatrix’s lead product in the treatment and prevention of several different respiratory infectious diseases.
